RetroSense Therapeutics to Highlight Contributions to Gene Therapy Research in Upcoming Conferences

ANN ARBOR, Mich.–(BUSINESS WIRE)– RetroSense Therapeutics, a privately-held biopharmaceutical company,
today announced that Chief Executive Officer Sean Ainsworth will
highlight RetroSense’s contributions to gene therapy research during
panel presentations at the NY BIO 2016 Annual Meeting and the Piper
Jaffray GenomeRx Symposium.

Chief Executive Officer Sean Ainsworth will participate in the Gene
Therapy – Understanding the Complexity & Applications of this New
Technology panel at the NY BIO 2016 Annual Meeting to be held at the
Time Warner Center in New York City. The panel presentation will take
place at 10:45 a.m. EDT on Thursday, May 12, 2016.

Ainsworth also will participate in a panel presentation at the Piper
Jaffray Genome RX Symposium at the Intercontinental NY Barclay in New
York City. The presentation, entitled Eyes on Gene Therapy for
Ophthalmology, will take place at 3:50 p.m. EDT on Tuesday, May 17,
2016.

RetroSense is developing optogenetic approaches to partial vision
restoration in retinitis pigmentosa and potentially dry age-related
macular degeneration. The Company’s lead product, RST-001 is being
developed as a first-in-class gene therapy application of optogenetics.
RST-001 is currently being tested in Phase I/II clinical studies.

About Optogenetics

Optogenetics refers broadly to means of conferring light sensitivity to
cells that were not previously, or natively light sensitive. By applying
optogenetics to retinas in which rod and cone photoreceptors have
degenerated, RetroSense is conferring new light sensitivity to the
retina, with the expectation of improved or restored vision. RST-001 is
expected to have application to all forms of Retinitis Pigmentosa,
independent of causative gene or mutation.

About Retinitis Pigmentosa

Retinitis pigmentosa is a genetic condition which leads to the
progressive degeneration of rod and cone photoreceptors (cells found in
the retina of the eye that sense light). Loss of these cells results in
severe vision loss and blindness.

About RetroSense Therapeutics

RetroSense Therapeutics is a privately-held biotechnology company
developing life-enhancing gene therapies designed to restore vision in
patients suffering from blindness due to retinitis pigmentosa (RP) and
advanced dry age-related macular degeneration (advanced dry-AMD). There
are currently no FDA approved drugs to improve or restore vision in
patients with these retinal degenerative conditions. The Company’s
approach to using optogenetics in vision restoration is based on
pioneering, proprietary research conducted at Wayne State University and
Massachusetts General Hospital. RetroSense has worldwide exclusive
rights to the relevant intellectual property from both institutions.
RetroSense is led by a team of seasoned veterans with deep experience in
taking products from the discovery stage through to the clinic. For more
information about RetroSense, visit http://www.retro-sense.com/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160505006082/en/